Status:

COMPLETED

Digoxin Versus Ivabradine in Heart Failure With Preserved Systolic Function

Lead Sponsor:

Cocco, Giuseppe, M.D.

Collaborating Sponsors:

Cardiology Office, Rheinfelden, Switzerland

Conditions:

Heart Failure

Atrial Fibrillation

Eligibility:

All Genders

60-78 years

Brief Summary

This is an investigator-started study. The trial is coded as no. GC\&PJ-Dig-Iva2009-2012. The authors have no conflict of interest and there was no financial sponsoring The study was planned accordin...

Detailed Description

Selected patients had chronic coronary artery disease which had been treated with percutaneous dilatation \& stenting and/or aortocoronary bypass. The severity of myocardial ischemia had induced heart...

Eligibility Criteria

Inclusion

  • No need to change concomitant pharmacological therapy in the following months, dyspnea class III NYHA, and abnormal left ventricular relaxation with preserved (≥52%) left ventricular ejection fraction (LVEF).

Exclusion

  • Unstable myocardial ischemia, reduced systolic cardiac function (LVEF\<52%), diabetes mellitus requiring insulin, moderate or severe renal or hepatic dysfunction, or technically insufficient echocardiography.

Key Trial Info

Start Date :

April 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

February 1 2012

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT01796093

Start Date

April 1 2008

End Date

February 1 2012

Last Update

February 1 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cardiology office

Rheinfelden, Canton of Aargau, Switzerland, CH-4310

Digoxin Versus Ivabradine in Heart Failure With Preserved Systolic Function | DecenTrialz